KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Current Deferred Revenue (2023 - 2025)

Astrana Health (ASTH) has disclosed Current Deferred Revenue for 3 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 65.57% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, up 65.57% year-over-year, with the annual reading at $2.7 million for FY2025, 65.57% up from the prior year.
  • Current Deferred Revenue hit $2.7 million in Q4 2025 for Astrana Health, up from $686000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.7 million in Q4 2025 to a low of $686000.0 in Q1 2025.
  • Historically, Current Deferred Revenue has averaged $1.8 million across 3 years, with a median of $1.9 million in 2024.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 115.86% in 2024 and later soared 65.57% in 2025.
  • Year by year, Current Deferred Revenue stood at $744000.0 in 2023, then surged by 115.86% to $1.6 million in 2024, then skyrocketed by 65.57% to $2.7 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ASTH at $2.7 million in Q4 2025, $686000.0 in Q1 2025, and $1.6 million in Q4 2024.